BSE Live
Nov 06, 16:01Prev. Close
197.00
Open Price
197.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 06, 15:55Prev. Close
197.31
Open Price
196.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Suven Life Sciences (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -1.08 | 3.08 | 12.45 | 9.69 | 7.83 | |
| Diluted EPS (Rs.) | -1.08 | 3.08 | 12.45 | 9.69 | 7.83 | |
| Cash EPS (Rs.) | -0.75 | 3.93 | 14.12 | 11.38 | 9.24 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 30.46 | 31.56 | 68.09 | 57.47 | 48.98 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 30.46 | 31.56 | 68.09 | 57.47 | 48.98 | |
| Dividend / Share(Rs.) | 0.00 | 1.50 | 1.50 | 1.00 | 2.00 | |
| Revenue from Operations/Share (Rs.) | 1.13 | 22.44 | 49.12 | 42.70 | 39.25 | |
| PBDIT/Share (Rs.) | -1.67 | 5.97 | 20.13 | 14.65 | 11.72 | |
| PBIT/Share (Rs.) | -2.00 | 5.12 | 18.45 | 12.97 | 10.35 | |
| PBT/Share (Rs.) | -2.04 | 4.97 | 18.09 | 12.52 | 9.88 | |
| Net Profit/Share (Rs.) | -1.08 | 3.08 | 12.45 | 9.70 | 7.86 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -147.26 | 26.58 | 40.97 | 34.30 | 29.86 | |
| PBIT Margin (%) | -176.17 | 22.80 | 37.56 | 30.36 | 26.36 | |
| PBT Margin (%) | -179.92 | 22.14 | 36.82 | 29.31 | 25.18 | |
| Net Profit Margin (%) | -95.41 | 13.71 | 25.33 | 22.71 | 20.03 | |
| Return on Networth / Equity (%) | -3.54 | 9.75 | 18.27 | 16.87 | 16.05 | |
| Return on Capital Employed (%) | -6.35 | 15.28 | 26.18 | 16.21 | 14.95 | |
| Return on Assets (%) | -3.35 | 8.91 | 15.61 | 14.09 | 12.93 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.04 | 0.08 | 0.11 | |
| Asset Turnover Ratio (%) | 3.51 | 65.00 | 61.63 | 62.03 | 64.55 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 5.19 | 21.18 | 4.79 | 4.25 | 4.08 | |
| Quick Ratio (X) | 5.19 | 21.18 | 3.60 | 3.45 | 3.28 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 4.48 | 5.88 | 5.98 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 12.05 | 10.30 | 39.79 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 10.62 | 8.78 | 33.87 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 87.95 | 89.70 | 60.21 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 89.38 | 91.22 | 66.13 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 272.34 | 3,322.09 | 2,147.26 | 2,160.22 | 2,279.12 | |
| EV/Net Operating Revenue (X) | 18.89 | 11.63 | 3.43 | 3.97 | 4.56 | |
| EV/EBITDA (X) | -12.83 | 43.74 | 8.38 | 11.59 | 15.28 | |
| MarketCap/Net Operating Revenue (X) | 18.90 | 11.62 | 3.42 | 3.88 | 4.91 | |
| Retention Ratios (%) | 0.00 | 0.00 | 87.94 | 89.69 | 60.20 | |
| Price/BV (X) | 0.70 | 8.27 | 2.46 | 2.88 | 3.94 | |
| Price/Net Operating Revenue | 18.90 | 11.62 | 3.42 | 3.88 | 4.91 | |
| Earnings Yield | -0.05 | 0.01 | 0.07 | 0.06 | 0.04 |
13.05.2025
Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y
28.01.2025
Suven Life Sci Consolidated December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
27.01.2025
Suven Life Sci Standalone December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
08.01.2025
Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug
13.05.2025
Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y
28.01.2025
Suven Life Sci Consolidated December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
27.01.2025
Suven Life Sci Standalone December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
30.10.2024
Suven Life Sci Consolidated September 2024 Net Sales at Rs 2.57 crore, down 15.91% Y-o-Y